<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00647153</url>
  </required_header>
  <id_info>
    <org_study_id>04085</org_study_id>
    <secondary_id>P30CA033572</secondary_id>
    <secondary_id>CHNMC-04085</secondary_id>
    <secondary_id>CDR0000590136</secondary_id>
    <nct_id>NCT00647153</nct_id>
  </id_info>
  <brief_title>Immunoscintigraphy Using Radiolabeled Monoclonal Antibody in Finding Tumor Cells in Patients With Colorectal Cancer</brief_title>
  <official_title>Pre-Surgical Detection of Colorectal Carcinomas Using 123Iodine-Labeled cT84.66 Diabody Antibody Fragments to Carcinoembryonic Antigen (CEA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Diagnostic procedures, such as immunoscintigraphy, using a radiolabeled monoclonal
      antibody may help find and diagnose colorectal cancer.

      PURPOSE: This clinical trial is studying how well immunoscintigraphy using a radiolabeled
      monoclonal antibody works in finding tumor cells in patients with colorectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To determine the ability of iodine I 123 anti-CEA recombinant diabody T84.66 to localize
           to colorectal cancer, as determined by quantitative radioimmunoscintigraphy in patients
           with colorectal cancer.

      Secondary

        -  To evaluate the clinical pharmacokinetics of iodine I 123 anti-CEA recombinant diabody
           T84.66 clearance in these patients.

        -  To characterize the frequency and titer of the human anti-chimeric response to iodine I
           123 anti-CEA recombinant diabody T84.66 in these patients.

        -  To determine the safety of iodine I 123 anti-CEA recombinant diabody T84.66 in these
           patients.

      OUTLINE: Patients receive an infusion of iodine I 123 anti-CEA recombinant diabody T84.66.
      Patients undergo planar imaging every 5 minutes during the radiolabeled antibody infusion and
      then at 3-6 hrs, 12-24 hours, and, if indicated, 30-48 hours after the radiolabeled antibody
      infusion. Planar spot images of the head, chest, abdomen, and pelvis and whole body images
      (anterior and posterior) are taken. Patients also undergo SPECT scan of the abdomen and
      pelvis at 12 and 24 hours after the radiolabeled antibody infusion.

      Blood samples are collected for pharmacokinetic analysis immediately after the radiolabeled
      antibody infusion and then at 15 minutes, 30 minutes, 1 hour, 2 hours, and 4 hours after the
      radiolabeled antibody infusion.

      Patients are followed periodically for 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor targeting properties of iodine I 123 anti-CEA recombinant diabody T84.66</measure>
    <time_frame>Day 2 post infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical pharmacokinetics of iodine I 123 anti-CEA recombinant diabody T84.66</measure>
    <time_frame>Day 2 post infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity properties of iodine I 123 anti-CEA recombinant diabody T84.66</measure>
    <time_frame>6 months post infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of iodine I 123 anti-CEA recombinant diabody T84.66</measure>
    <time_frame>6 months post infusion</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Radiation: iodine I 123 anti-CEA recombinant diabody T84.66</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Pre-infusion and 30 min., 1h,2h, and 3-4h post start of infusion. Day 1 and 2 post infusion.</description>
    <arm_group_label>Radiation: iodine I 123 anti-CEA recombinant diabody T84.66</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>single photon emission computed tomography</intervention_name>
    <description>One day post infusion</description>
    <arm_group_label>Radiation: iodine I 123 anti-CEA recombinant diabody T84.66</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>iodine I 123 anti-CEA recombinant diabody T84.66</intervention_name>
    <description>10mCi/mg</description>
    <arm_group_label>Radiation: iodine I 123 anti-CEA recombinant diabody T84.66</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed colorectal cancer

               -  Stage I-IV disease

        PATIENT CHARACTERISTICS:

          -  Serum creatinine &lt; 2.0 mg/dL

          -  Total bilirubin &lt; 2.0 mg/dL

          -  Hemoglobin &gt; 9.0 g/dL

          -  cT84.66 antibody negative (if previously treated with mouse or chimeric
             immunoglobulins)

          -  Not pregnant

          -  No condition that, in the opinion of the investigator, would preclude study compliance

          -  No known allergy to iodine

          -  No known history of HIV, hepatitis B, or hepatitis C

        PRIOR CONCURRENT THERAPY:

          -  No concurrent steroids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Y. Wong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2008</study_first_submitted>
  <study_first_submitted_qc>March 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2008</study_first_posted>
  <last_update_submitted>November 2, 2017</last_update_submitted>
  <last_update_submitted_qc>November 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I colon cancer</keyword>
  <keyword>stage II colon cancer</keyword>
  <keyword>stage III colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage I rectal cancer</keyword>
  <keyword>stage II rectal cancer</keyword>
  <keyword>stage III rectal cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Iodine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

